Trial · NCT07894614
Ablation Versus Non-ablation Strategies for Non-puerperal Mastitis: A Prospective Real-world Registry Study
NCT07894614, Recruiting, Song Hongping
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ablation Versus Non-ablation Strategies for Non-puerperal Mastitis: A Prospective Real-world Registry Study. Trials, record NCT07894614. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894614
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ablation Versus Non-ablation Strategies for Non-puerperal Mastitis: A Prospective Real-world Registry Study
- NCT number
- NCT07894614
- Status
- Recruiting
- Enrollment
- 340 participants, estimated
- Lead sponsor
- Song Hongping
- Conditions
- Non-Puerperal Mastitis
- Interventions
- Ablation, Observation
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1-year complete remission | From enrollment up to 1 year post-treatment completion | Complete disappearance of clinical symptoms and complete resolution of target lesions on imaging evaluation within 1 year. |
| Secondary | Time to Complete Remission | From enrollment up to 1 year post-treatment completion | Complete disappearance of clinical symptoms and complete resolution of target lesions on imaging evaluation. |
| Secondary | 1-Year Partial Response | From enrollment up to 1 year post-treatment completion | Improvement in all clinically significant symptoms, including pain, swelling, erythema, and induration, within 1 year; OR at least a 30% decrease in the sum of target lesion diameters relative to the baseline sum. |
| Secondary | 1-Year Overall Response | From enrollment up to 1 year post-treatment completion | Achieving either complete remission (CR) or partial remission (PR) criteria within 1 year. |
| Secondary | Non-Response | From enrollment up to 1 year post-treatment completion | Target lesion shrinkage is insufficient to meet PR criteria, or disease progression, new ulceration, or fistula formation occurs during treatment. |
| Secondary | Recurrence Rate | From enrollment up to 3 month post-treatment completion | Disease recurrence 3 months after achieving clinical and ultrasound-confirmed complete remission. |
| Secondary | Time to Recurrence | From enrollment up to 3 month post-treatment completion | Disease recurrence 3 months after achieving clinical and ultrasound-confirmed complete remission. |
| Secondary | M-SCORE | From enrollment up to 1 year post-treatment completion | a clinical severity scoring system for non-puerperal mastitis, consisting of mass, erythema, pain, fistula and abscess subscores. Higher scores indicate more severe disease. |
| Secondary | Breast satisfaction (BREAST-Q score) | From enrollment up to 1 year post-treatment completion | a validated patient-reported outcome questionnaire to assess breast satisfaction, psychosocial well-being, physical well-being and sexual well-being. Scores range from 0 to 100; higher scores indicate better patient-reported outcomes. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894614
GET https://conductscience.org/api/trials/v1/NCT07894614/registered